REQUEST FOR APPLICATIONS (RFA)

The Samuel Waxman Cancer Research Foundation (SWCRF), the Israel Cancer Research Fund (ICRF) and the Alan B. Slifka Foundation (ABSF) are pleased to announce a special Request for Applications (RFA) for a total of two, two-year awards of $125,000/year. These awards, so named the Max Ritvo, Alan Slifka and Desiree Dato Fund for Fusion-Oncoprotein Cancers and Metastasis, should address at least one of the following topics:

1- Cancers driven by fusion oncoproteins with Ewing sarcoma as the prototype.

2- The roles of epigenetic dysfunction or tumor microenvironment in the development of metastatic cancer

This is a grant to support collaborative science conducted by co-investigators in the United States of America (USA) and Israel.

Directors of cancer research programs in the USA and Israel are invited to submit one application per institution. Collaborating laboratories based in USA and in Israel, the science it will conduct, and integration of the two efforts must be identified. $125,000 total will be awarded to a USA based investigator and $125,000 to an Israeli investigator.

Themes of research funded by the Foundations in the past have included:

- Transcription-based approaches to cancer
- Novel therapies/pathways to overcome defective differentiation of cancer cells
- The study of chromosomal translocations, the oncogenes they generate and their role in cancers like sarcoma
- Modeling of the processes of metastases and drug resistance
- Targeting aberrant signaling pathways characteristic of the malignant phenotype
- Selective apoptotic agents and pathways

Recipients of these awards are encouraged to develop collaborations with other investigators to continue scientific interactions beyond the term of their grant and form a society of investigators committed to:

Collaboration:

- Formulation of research plans to augment other SWCRF/ICRF/ABSF research programs
- Sharing of research materials, reagents, and/or core resources
- Joint publications
- Development of NIH program project grants (P01s) and/or collaborative R01s
Communication:

- Presentation at an annual Scientific Review Meeting hosted by the SWCRF
- Subgroup meetings at professional meetings such as ASH, AACR and CTOS

2020 RFA Guidelines

Each center may nominate one Principal Investigator with an Israel-based collaborator to apply for a two-year grant for up to $250,000 ($125,000 per year): $125,000 directed to the USA and $125,000 to Israel.

Timeline:

- Submit a one-page letter of intent (LOI) using the template below
- Invitations for Full Application
- Full application
- Funding decision

March 15, 2020

April 15, 2020

June 1, 2020

July 1, 2020

Funding decisions will be made by peer review by members of the SWCRF Scientific Advisory Board, the ICRF Scientific Advisory Board, and the ABSF Medical Advisory Council. Reporting results and the budget process will be discussed at the time of announcement of the awards.

Submit all inquiries and responses to Mr. Jesse Dean jdean@waxmancancer.org and Ms. Lyris Skinner lyris.skinner@mssm.edu.

About the SWCRF

The Samuel Waxman Cancer Research Foundation (SWCRF), founded in 1975, is a non-profit organization dedicated to conducting basic, translational, and clinical research with the goal of developing effective targeted treatments for cancer. SWCRF funds research in leading institutions in the United States, Canada, China, and Israel; fosters collaborations; trains scientists; and organizes international conferences to develop novel approaches to prevent and treat cancer. SWCRF develops research programs in the form of an “Institution Without Walls™” that spans institutions and disciplines and seeks to identify investigators who are best able to attack specific problems related to cancer.

About the ICRF

Israel Cancer Research Fund, a 501(c)(3) organization, is the largest nationwide charitable organization in North America solely devoted to supporting cancer research in Israel. Since its establishment in 1975, ICRF has provided nearly 2,500 grants to outstanding cancer researchers whose laboratories are located in all of the leading research institutions, universities and hospitals across Israel. These grants are for research proposed by Israeli investigators and peer-reviewed to be of high priority by a select group of senior North American cancer scientists.

About the Alan B. Slifka Foundation

Founded in 1965, the Alan B. Slifka Foundation is a private family foundation dedicated to the pursuit of inclusion, diversity, peace and healing. The Foundation seeks to combat cancer, especially childhood cancer, through the support of innovative biomedical research. Among the Foundation’s top priorities is funding research into less toxic, more effective and potentially curative therapies for a variety of cancers, but especially for connective tissue cancers, known as sarcomas, that disproportionately impact children and young adults. The Alan B. Slifka Foundation is particularly interested in supporting bench-to-bedside research that results in targeted therapies, and also research that enhances our understanding of the metastatic process.
Letter of Intent (1 page)

The Max Ritvo, Alan Slifka and Desiree Dato Fund for Fusion-Oncoprotein Cancers and Metastasis
Samuel Waxman Cancer Research Foundation
Israel Cancer Research Fund
The Alan B. Slifka Foundation

Title:

PI name, USA Institution:

PI name, Israel Institution:

Background:

Key preliminary data:

Premise and rigor of underlying research:

Hypothesis:

Specific Aims:

Evidence for collaboration synergism:

Novelty:

Potential translational impact to cancer: